Injection Pen Market

The Injection Pen Market is valued at USD 45.4 Bn in 2026 and is projected to reach USD 74.6 Bn,  growing at a CAGR of 6% by 2033.

This study intends to analyse diverse aspects of the global injection pen market. The insights offered in this report are expected to aid in market growth examination over the forecast timeline. In 2021, the market reflected modest growth and per industry figures, it stood at around US$37 Bn in terms of value. According to preliminary study carried out by Fairfield Market Research, the injection pen industry will continue to grow at a healthy pace in the next seven years.

• High prevalence of chronic diseases to drive the growth of the injection pen market
• Increasing use of insulin pens to augur well for the market
• Functional benefits offered by injection pens to bolster market growth
• Asia Pacific to present potential opportunities for the market
• North America likely to dominate the worldwide injection pen industry

Rising Demand for Insulin Pens

Since past several years, diabetes cases have been on the rise thus giving an impetus to the use of insulin pens. For instance, according to the International Diabetes Federation 2021 report, more than 530 million adult individuals in the age range of 20 to 79 years are suffering from diabetes. The overall count of individuals with diabetes is expected to increase to cross 640 million by end of 2030 and reach approximately 780 million by end of 2045. Furthermore, about one in two individuals with diabetes are not diagnosed. This has resulted in an increase in the demand for advanced drug delivery systems replacing conventional methods.

Insulin pens are gaining high traction on the back of their advantages such as high accuracy of insulin delivery and user friendliness. In addition, growing availability of smart insulin pens with different dosages and prefilled designs has further boosted their demand and sales. These factors have paved an opportunistic scenario for insulin pens, consequently driving the growth of the injection pen market.

Benefits and Usability of Medication Injectors in Different Medical Conditions

Injection pens have gained considerable recognition as effective drug delivery solutions worldwide. With the rising burden of chronic ailments, the demand for injection pens has soared since the past years and is expected to maintain status quo in the forthcoming years. In addition, apart from diabetes, injection pens are widely used to deliver medications to individuals suffering from other medical conditions including rheumatoid arthritis.

Furthermore, convenience being a major feature of injection pens, they provide ease if grip. Also, self-injection of medication is possible using injection pens. Moreover, injection pen relives the individual from burden of carrying vials and syringes of medications. In this backdrop, high prevalence of chronic diseases coupled with functional benefits of injectors is expected to augur well for the injection pen market.

Overview of Key Segments

Reusable Injectors Account for a Significant Value Share

As compared to disposable injections, reusable counterparts have been gaining high traction and are expected to largely contribute toward the value growth of the injection pen market. Disposable injection pens come with fixed medication dosage and need to be disposed after use or when they reach their expiry date.

On the other hand, reusable injection pens require periodic loading of dosage and cartridge. In this case, replacement of cartridge and needles is carried out. This increases their service life and can be used for several years. That said, reusable injection pens are cost efficient, and have high durability. In addition, they are discreet and convenient from a usage standpoint. These factors have fuelled the use of reusable injectors, in turn complementing the growth of the injection pen market.

Growth Opportunities Across regions      

North America to Slate Dominance

From a geographical standpoint, the developed economies in North America are expected to account for a significant revenue share in the injection pen market. This can be attributed toward increasing prevalence of chronic diseases across countries such as United States, and Canada. For instance, according to National Institutes of Health’s National Center for Biotechnology Information, number of individuals in the United States in the age range of 50 years and above is expected to reach more than 221 million by end of 2050. Among these, the number of individuals suffering from at least one chronic disease is projected to increase from 71 million in 2020 to around 142 million by end of 2050.

In addition, the number of individuals suffering from multimorbidity is expected to increase from 7 million in 2020 to more than 14 million by the end of 2050. This has resulted in an increase in demand for effective and safe delivery of medications, in turn propelling the use of injection pens. Furthermore, other macroeconomic factors such as strong economic growth, presence of major players involved in the manufacturing of injection pens, rising GDP per capita, favourable healthcare infrastructure and favourable government support have further fuelled the growth of the injection pen market in North America.

Asia Pacific to Emerge Lucrative

On the other side of the spectrum, Asia Pacific is likely to soar at a high pace in the injection pen market. Rising patient pool backed by ever increasing population and coupled with proliferation of chronic diseases such as cancers, and diabetes have largely contributed toward the growth of the market in the region. In addition, growing accessibility to healthcare and medications, use of advanced technologies and improving medical infrastructure have influenced the market in Asian countries such as China, and India.

Moreover, several players have tapped the region for its high lucrativeness apropos to favourable business environment. This has largely contributed toward the value growth of the injection pen market in the Asia Pacific region. Overall, Asia Pacific reflects an optimistic scenario for market.

A few of the major players in the injection pen market include 

• Novo Nordisk A/S
• Eli Lilly and Company
• Sanofi
• BD (Becton, Dickinson and Company)
• Ypsomed AG
• Haselmeier AG
• Owen Mumford Ltd.
• Gerresheimer AG
• SHL Medical AG
• AptarGroup, Inc.
• Teva Pharmaceutical Industries Ltd.
• Pfizer Inc.
• Biocorp Production
• West Pharmaceutical Services, Inc.
• Nemera

Product